Abstract
Aims: Viral infections have been implicated in the development of Parkinson disease (PD). It has been observed that the presence of SARS-CoV-2 in dopaminergic cells can expedite the degeneration process and potentially exacerbate symptoms. The objective of this study was to assess the impact of the COVID-19 pandemic on individuals with PD.
 Methods: A total of 60 patients were enrolled in the study. The severity of the disease was assessed using the using the Unified Parkinson's Disease Rating Scale (UPDRS), while the stage of the disease was determined using modified Hoehn &Yahr Rating Scale (m HYRS). Various measures were taken to evaluate the patients’ well-being, including the Beck Depression Inventory (BDI), Beck Anxiety Inventory (BAI), Pittsburgh Sleep Quality Index (PSQI), Epworth Sleepiness Scale (ESS), Parkinson's Disease Quality of Life Questionnaire (PDQ-39), and Impact of Events Scale (IES-R) scores. The researchers also recorded the UPDRS scores, levodopa equivalent doses (LED), and BMI of the patients before and after the lockdown period. Subsequently, the collected data were compared to identify any significant changes.
 Results: The difference in UPDRS, LED and BMI of the patients before and after the lockdown was statistically significant (p
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
